A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1
Authors:
- Gabriela M. StieglerGSGabriela M. Stiegler
- Brigitta A. VcelarBVBrigitta A. Vcelar
- Walter JägerWJWalter Jäger
- Nelson L. MichaelNMNelson L. Michael
- Norbert VetterNVNorbert Vetter
- Hermann W. D. KatingerHKHermann W. D. Katinger
- 1 January 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health in AIDS
- Vol. 16 (2) , 227-233
Abstract
To study the safety, immunogenicity and pharmacokinetics of two intravenously administered human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1 in humans. Open label clinical phase I trial. Primary institutional care. Seven HIV-1-infected healthy volunteers with ≥ 500 × 106CD4 cells/l and ≤ 10 000 HIV-1 RNA copies/ml, not treated with highly active antiretroviral therapy (HAART), entered and finished the study. and main outcome measures: Eight separate infusions of the hMAb were administered over a 4-week period (total dose 14 g). The safety was assessed by physical examination, blood chemistry, complete blood cell count and recording adverse events. 2F5 and 2G12 plasma levels were determined prior to and at the end of each infusion and during the follow-up period of 22 weeks. No clinical or laboratory abnormalities were observed throughout the study. The median distribution half-life (t1/2α) of 2F5 and 2G12 was 1.02 (range, 0.77–1.47) days and 2.49 (range, 0.92–4.59) days, respectively. The elimination half-life (t1/2β) was calculated to be 7.94 (range, 3.46–8.31) days for 2F5 and 16.48 (range, 12.84–24.85) days for 2G12. The median plasma concentration immediately after the first infusion was 216 μg/ml (range, 158–409 μg/ml) for 2F5 and 238 μg/ml (range, 197–402 μg/ml) for 2G12. Multiple infusions resulted in maximum plasma concentrations of 374 μg/ml (range, 304–700 μg/ml) and 605 μg/ml (range, 479–897 μg/ml) for 2F5 and 2G12, respectively. This study showed that the hMAb 2F5 and 2G12 are safe and well tolerated by HIV-1-infected subjects.Keywords
This publication has 22 references indexed in Scilit:
- HIV-1 rebound after anti-retroviral therapyNature Medicine, 2000
- Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infectionNature Medicine, 2000
- Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodiesNature Medicine, 2000
- Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in AdultsNew England Journal of Medicine, 1999
- Longitudinal HIV-1 RNA Levels in a Cohort of Homosexual MenJAIDS Journal of Acquired Immune Deficiency Syndromes, 1998
- Phase I Study of a Human Monoclonal Antibody Directed against the CD4-Binding Site of HIV Type 1 Glycoprotein 120AIDS Research and Human Retroviruses, 1998
- A Broadly Neutralizing Human Monoclonal Antibody against gp41 of Human Immunodeficiency Virus Type 1AIDS Research and Human Retroviruses, 1994
- A Phase I/IIA Clinical Study With A Chimeric Mouse-Human Monoclonal Antibody To The V3 Loop Of Human Immunodeficiency Virus Type 1 Gp120The Journal of Infectious Diseases, 1994
- Generation of Human Monoclonal Antibodies against HIV-1 Proteins; Electrofusion and Epstein-Barr Virus Transformation for Peripheral Blood Lymphocyte ImmortalizationAIDS Research and Human Retroviruses, 1994
- PASSHIV-1 treatment of patients with HIV-1 infection. A preliminary report of a Phase I trial of hyperimmune porcine immunoglobulin to HIV-1AIDS, 1992